Abstract & Authors:展开
Neoadjuvant chemotherapy is a common treatment for patients with gastric cancer. Although its benefits have been demonstrated, neoadjuvant chemotherapy is underutilized in gastric cancer management, because of the lack of biomarkers for patient selection and a limited understanding of resistance mechanisms. Here, we performed whole-genome, whole-exome, and RNA sequencing on 84 clinical samples (including matched pre- and posttreatment tumors) from 35 patients whose responses to neoadjuvant chemotherapy were rigorously defined. We observed increased microsatellite instability and mutation burden in nonresponse tumors. Through comparisons of response versus nonresponse tumors and pre- versus posttreatment samples, we found that C10orf71 mutations were associated with treatment resistance, which was supported by drug response data and potentially through inhibition of cell cycle, and that MYC amplification correlated with treatment sensitivity, whereas MDM2 amplification showed the opposite pattern. Neoadjuvant chemotherapy also reshapes tumor-immune signaling and microenvironment. Our study provides a critical basis for developing precision neoadjuvant regimens.
Ziyu Li,Xiangyu Gao,Xinxin Peng,Mei-Ju May Chen,Zhe Li
Han Liang,Jiafu Ji
Ziyu Li,Xiangyu Gao,Xinxin Peng,Mei-Ju May Chen,Zhe Li,Bin Wei,Xianzi Wen,Baoye Wei,Yu Dong,Zhaode Bu,Aiwen Wu,Qi Wu,Lei Tang,Zhongwu Li,Yiqiang Liu,Li Zhang,Li Zhang,Lianhai Zhang,Fei Shan,Ji Zhang,Xiaojiang Wu,Xin Ji,Ke Ji,Xiaolong Wu,Jinyao Shi,Xiaofang Xing,Jianmin Wu,Guoqing Lv,Lin Shen,Xuwo Ji,Han Liang,Jiafu Ji